FDA Panel to Review Humira Colitis Data
(MedPage Today) — Further studies may be needed to demonstrate clear benefits for the tumor necrosis factor (TNF) inhibitor adalimumab (Humira) in ulcerative colitis, FDA staff suggested.
FDA Panel to Review Humira Colitis Data
(MedPage Today) — Further studies may be needed to demonstrate clear benefits for the tumor necrosis factor (TNF) inhibitor adalimumab (Humira) in ulcerative colitis, FDA staff suggested.
FDA Panel to Review Humira Colitis Data
(MedPage Today) — Further studies may be needed to demonstrate clear benefits for the tumor necrosis factor (TNF) inhibitor adalimumab (Humira) in ulcerative colitis, FDA staff suggested.
FDA Panel to Review Humira Colitis Data
(MedPage Today) — Further studies may be needed to demonstrate clear benefits for the tumor necrosis factor (TNF) inhibitor adalimumab (Humira) in ulcerative colitis, FDA staff suggested.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com